arrow
R

Ranjit S. Bindra

Yale School of Medicine
H指数:44
被引数:9,513

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The PRIME trial: An investigator-initiated, multicentre, phase II study of the poly(ADP-ribose) polymerase inhibitor olaparib in isocitrate dehydrogenase (IDH)-mutated relapsed/refractory acute myeloid leukaemia and myelodysplastic syndromes

PRIME试验:一项由研究者发起的多中心II期研究,评估聚(ADP-核糖)聚合酶抑制剂奥拉帕利在异柠檬酸脱氢酶(IDH)突变复发/难治性急性髓系白血病和骨髓增生异常综合征中的应用

2026-09-060
OAAI
A genetic platform to deconvolve efficacy and toxicity reveals the on-target effects of CDK11 inhibition in vivo

一个用于解析功效和毒性的遗传平台揭示了CDK11抑制在体内的靶向效应

2026-01-010
OAAI
Phase I/II and window-of-opportunity study of pamiparib and metronomic temozolomide for recurrent isocitrate dehydrogenase mutant gliomas

I期/II期和机会窗口研究:帕米帕利布与常规替莫唑胺联合治疗异柠檬酸脱氢酶突变型胶质瘤的复发病例

2025-10-160
PRE
Systemic administration of an RNA binding and cell-penetrating antibody targets therapeutic RNA to multiple mouse models of cancer

系统性给予一种具有RNA结合能力和细胞穿透作用的抗体,可将治疗性RNA靶向递送至多种癌症小鼠模型。

2025-07-160
PRE
Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial

奥拉帕尼治疗难治性异柠檬酸脱氢酶1 (IDH1) 和IDH2-mutant胆管癌: 来自美国国家癌症研究所10129期2试验的安全性和抗肿瘤活性

CANCER
IF5.1
2025-02-070
PRE
Central nervous system tumors in adolescents and young adults: A Society for Neuro-Oncology consensus review on diagnosis, management, and future directions
2024-10-230
PRE
Systemic targeting of therapeutic RNA to pancreatic ductal adenocarcinoma via a novel, cell-penetrating, and nucleic acid-binding monoclonal antibody
2024-09-150
PRE